Association between plasma biomarkers, CDK5 polymorphism and the risk of Alzheimer's disease

• Autorzy: Czapski G.A. , Maruszak A. , Styczynska M. , Zekanowski C. , Safranow K. , Strosznajder J. B.
• Języki publikacji: EN

Abstrakty

EN

In this study we evaluated biochemical blood serum parameters and the association of Cyclin-dependent kinase 5 (CDK5) gene polymorphisms with the risk of Alzheimer's disease (AD) in the Polish population. We observed an elevated total cholesterol, low-density lipoproteins (LDL) and homocysteine levels and lower concentrations of high-density lipoproteins (HDL) and vitamin B12 in AD patients. However, the analyzed CDK5 polymorphisms were not associated with the biochemical parameters. Moreover, we found no association between the studied polymorphisms and the risk of AD in the Polish population. The meta-analysis of previously published and current study was performed. In conclusion, our study demonstrated that alteration of cholesterol, LDL, HDL, homocysteine and B12 concentration may be an important factor in pathogenesis of AD.

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2012
• Tom: 72
• Numer: 4
• Opis fizyczny: p.397-411,fig.,ref.

Twórcy

autor

Czapski G.A.

• Department of Cellular Signalling, Polish Academy of Sciences, Warsaw, Poland

autor

Maruszak A.

• Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Styczynska M.

• Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Zekanowski C.

• Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Safranow K.

• Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Szczecin, Poland

autor

Strosznajder J. B.

• Department of Cellular Signalling, Polish Academy of Sciences, Warsaw, Poland

Bibliografia

• Alvarez A, Toro R, Caceres A, Maccioni RB (1999) Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett 459: 421-426.
• Arias-Vasquez A, Aulchenko YS, Isaacs A, van Oosterhout A, Sleegers K, Hofman A, Van Broeckhoven C, Oostra BA, Breteler M, van Duijn CM (2008) Cyclin-dependent kinase 5 is associated with risk for Alzheimer's disease in a Dutch population-based study. J Neurol 255: 655-662.
• Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
• Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E (1993) Abnormal Alzheimer-like phospho¬rylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 336: 417-424.
• Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39: 17-23.
• Blacker D, Haines JL, Rodes L, Terwedow H, Go RC, Harrell LE, Perry RT, Bassett SS, Chase G, Meyers D, Albert MS, Tanzi R (1997) ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology 48: 139-147.
• Chu J, Giannopoulos PF, Ceballos-Diaz C, Golde TE, Pratico D (2012) 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of alzheimer disease. Ann Neurol 72: 442-454.
• Chung SH (2009) Aberrant phosphorylation in the patho- genesis of Alzheimer's disease. BMB Rep 42: 467-474.
• Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak- Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923. Dong W, Vuletic S, Albers JJ (2009) Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J Lipid Res 50: 2095-2102.
• Eckert GP, Wood WG, Müller WE (2005) Statins: drugs for Alzheimer's disease? J Neural Transm 112: 1057-1071.
• Fan QW, Yu W, Senda T, Yanagisawa K, Michikawa M (2001) Cholesterol-dependent modulation of tau phos- phorylation in cultured neurons. J Neurochem 76: 391¬400.
• Flicker L, Martins RN, Thomas J, Acres J, Taddei K, Vasikaran SD, Norman P, Jamrozik K, Almeida OP (2008) B-vitamins reduce plasma levels of beta amyloid. Neurobiol Aging 29: 303-305.
• Galbete JL, Martin TR, Peressini E, Modena P, Bianchi R, Forloni G (2000) Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. Biochem J 348: 307-313.
• Harold D, Abraham R, Hollingworth P (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41: 1088-1093.
• Heid CA, Stevens J, Livak KJ, Williams PM (1996) Real time quantitative PCR. Genome Res 6: 986-994.
• Henderson JN, Crook R, Crook J, Hardy J, Onstead L, Carson- Henderson L, Mayer P, Parker B, Petersen R, Williams B (2002) Apolipoprotein E4 and tau allele frequencies among Choctaw Indians. Neurosci Lett 324: 77-79.
• Iijima K, Ando K, Takeda S, Satoh Y, Seki T, Itohara S, Greengard P, Kirino Y, Nairn AC, Suzuki T (2000) Neuron-specific phosphorylation of Alzheimer's beta- amyloid precursor protein by cyclin-dependent kinase 5. J Neurochem 75: 1085-1091.
• Ikeda T, Furukawa Y, Mashimoto S, Takahashi K, Yamada M (1990) Vitamin B12 levels in serum and cerebrospinal fluid of people with Alzheimer's disease. Acta Psychiatr Scand 82: 327-329.
• Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, et al. (2010) Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One 5: e13950.
• Konings PN, Philipsen RL, Veeneman GH, Ruigt GS (1994) Alpha-sialyl cholesterol increases laminin in Schwann cell cultures and attenuates cytostatic drug-induced reduc¬tion of laminin. Brain Res 654: 118-128.
• Koudinov AR, Koudinova NV (2005) Cholesterol homeo- stasis failure as a unifying cause of synaptic degeneration. J Neurol Sci 229-230: 233-240.
• Kölsch H, Heun R, Jessen F, Popp J, Hentschel F, Maier W, Lütjohann D (2010) Alterations of cholesterol precursor levels in Alzheimer's disease. Biochim Biophys Acta 1801: 945-950.
• Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, Roher AE (1998) Elevated low- density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 252: 711-715.
• Lambert JC, Heath S, Even G (2009) Genome-wide associa¬tion study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41: 1094-1099.
• Lau KF, Howlett DR, Kesavapany S, Standen CL, Dingwall C, McLoughlin DM, Miller CC (2002) Cyclin-dependent kinase-5/p35 phosphorylates Presenilin 1 to regulate car- boxy-terminal fragment stability. Mol Cell Neurosci 20: 13-20.
• Lazaro JB, Kitzmann M, Poul MA, Vandromme M, Lamb NJ, Fernandez A (1997) Cyclin dependent kinase 5, cdk5, is a positive regulator of myogenesis in mouse C2 cells. J Cell Sci 110: 1251-1260.
• Leblhuber F, Walli J, Artner-Dworzak E, Vrecko K, Widner B, Reibnegger G, Fuchs D (2000) Hyperhomocysteinemia in dementia. J Neural Transm 107: 1469-1474.
• Lee CH, Wei YW, Huang YT, Lin YT, Lee YC, Lee KH, Lu PJ (2010) CDK5 phosphorylates eNOS at Ser-113 and regulates NO production. J Cell Biochem 110: 112-117.
• Lee KY, Clark AW, Rosales JL, Chapman K, Fung T, Johnston RN (1999) Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci Res 34: 21-29.
• Lesser GT, Beeri MS, Schmeidler J, Purohit DP, Haroutunian V (2011) Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles. Curr Alzheimer Res 8: 303-312.
• Li BS, Sun MK, Zhang L, Takahashi S, Ma W, Vinade L, Kulkarni AB, Brady RO, Pant HC (2001) Regulation of NMDA receptors by cyclin-dependent kinase-5. Proc Natl Acad Sci USA 98: 12742-12747.
• Li H, Wetten S, Li L, St Jean PL, Upmanyu R, et al. (2008) Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 65: 45-53.
• Li Q, Liu X, Zhang M, Ye G, Qiao Q, Ling Y, Wu Y, Zhang Y, Yu L (2010) Characterization of a novel human CDK5 splicing variant that inhibits Wnt/beta-catenin signaling. Mol Biol Rep 37: 2415-2421.
• Lopes JP, Oliveira CR, Agostinho P (2010) Neurodegeneration in an Abeta-induced model of Alzheimer's disease: the role of Cdk5. Aging Cell 9: 64-77.
• Ma T, Zhao Y, Kwak YD, Yang Z, Thompson R, Luo Z, Xu H, Liao FF (2009) Statin's excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-in- duced truncation events, likely via rho-ROCK signaling. J Neurosci 29: 11226-11236.
• Mathew A, Yoshida Y, Maekawa T, Kumar DS (2011) Alzheimer's disease: cholesterol a menace? Brain Res Bull 86: 1-12.
• Memon RA, Grunfeld C, Moser AH, Feingold KR (1993) Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 132: 2246-2253.
• Mielke MM, Zandi PP, Shao H, Waern M, Ostling S, Guo X, Bjorkelund C, Lissner L, Skoog I, Gustafson DR (2010) The 32-year relationship between cholesterol and demen¬tia from midlife to late life. Neurology 75: 1888-1895.
• Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
• Morfini G, Szebenyi G, Brown H, Pant HC, Pigino G, DeBoer S, Beffert U, Brady ST (2004) A novel CDK5- dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J 23: 2235¬2245.
• Nilsson K, Gustafson L, Hultberg B (2012) elevated plasma homocysteine level is not primarily related to Alzheimer's disease. Dement Geriatr Cogn Disord 34: 12-127.
• Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, Weitz JI, Austin RC (1999) Homocysteine-induced endo- plasmic reticulum stress and growth arrest leads to spe¬cific changes in gene expression in human vascular endothelial cells. Blood 94: 959-967.
• Pigino G, Paglini G, Ulloa L, Avila J, Caceres A (1997) Analysis of the expression, distribution and function of cyclin dependent kinase 5 (cdk5) in developing cerebellar macroneurons. J Cell Sci 110: 257-270.
• Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer's dis¬ease: the cholesterol connection. Nat Neurosci 6: 345¬351.
• Rademakers R, Sleegers K, Theuns J, van den Broeck M, Bel Kacem S, Nilsson LG, Adolfsson R, van Duijn CM, van Broeckhoven C, Cruts M (2005) Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onset alzheimer's disease. Neurobiol Aging 26: 1145-1151.
• Raygani AV, Rahimi Z, Kharazi H, Tavilani H, Pourmotabbed T (2006) Association between apolipoprotein E polymor¬phism and serum lipid and apolipoprotein levels with Alzheimer's disease. Neurosci Lett 408: 68-72.
• Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, et al. (2007) GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 54: 713-720.
• Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA (2010) Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol 67: 1491-1497.
• Religa D, Styczynska M, Peplonska B, Gabryelewicz T, Pfeff er A, Chodakowska M, Luczywek E, Wasiak B, Stepien K, Golebiowski M, Winblad B, Barcikowska M (2003) Homocysteine, apolipoproteine E and methyle- netetrahydrofolate reductase in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 16: 64-70.
• Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59: 223-227.
• Sanghera DK, Ortega L, Han S, Singh J, Ralhan SK, Wander GS, Mehra NK, Mulvihill JJ, Ferrell RE, Nath SK, Kamboh MI (2008) Impact of nine common type 2 diabe¬tes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk. BMC Med Genet 9: 59.
• Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS (2011) A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77: 556-563.
• Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid beta-peptide deposi¬tion in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset alzheimer disease. Proc Natl Acad Sci U S A 90: 9649-9653.
• Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, et al. (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303: 1832-1840.
• Shukla V, Zheng YL, Mishra SK, Amin ND, Steiner J, Grant P, Kesavapany S, Pant HC (2012) A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice. FASEB J (Epub ahead of print).
• Small SA, Duff K (2008) Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60: 534-542.
• Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA (2009) Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord 28: 75-80.
• Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, RosesAD (1993)Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90: 1977-1981.
• Styczyńska M, Strosznajder JB, Religa D, Chodakowska- Zebrowska M, Pfeffer A, Gabryelewicz T, Czapski GA, Kobryś M, Karciauskas G, Barcikowska M (2008) Association between genetic and environmental factors and the risk of Alzheimer's disease. Folia Neuropathol 46: 249-254.
• Tseng HC, Zhou Y, Shen Y, Tsai LH (2002) A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett 523: 58-62.
• Utreras E, Futatsugi A, Rudrabhatla P, Keller J, Iadarola MJ, Pant HC, Kulkarni AB (2009) Tumor necrosis factor-al¬pha regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35. J Biol Chem 284: 2275-2284.
• Vafai SB, Stock JB (2002) Protein phosphatase 2A methylation: a link between elevated plasma homocysteine and Alzheimer's disease. FEBS Lett 518: 1-4.
• van Haperen R, de Waard M, van Deel E, Mees B, Kutryk M, van Aken T, Hamming J, Grosveld F, Duncker DJ, de Crom R (2002) Reduction of blood pressure, plasma cho¬lesterol, and atherosclerosis by elevated endothelial nitric oxide. J Biol Chem 277: 48803-48807.
• Vázquez-Higuera JL, Mateo I, Sánchez-Juan P, Rodríguez- Rodríguez E, Infante J, Berciano J, Combarros O (2009) No association of CDK5 genetic variants with Alzheimer's disease risk. BMC Med Genet 10: 68.
• Warren MW, Hynan LS, Weiner MF (2012) Lipids and adipokines as risk factors for Alzheimer's disease. J Alzheimers Dis 29: 151-157.
• Wehr H, Bednarska-Makaruk M, Graban A, Kunicki PK, Lojkowska W, Rodo M, Ryglewicz D (2003) Apolipoprotein E polymorphism and low density lipopro¬tein (LDL) oxidation in patients with dementia. Folia Neuropathol 41: 65-68.
• Xu Y, Kim Zhang J, Krishnamurthy PK, Johnson GV (2002) Cdk5 phosphorylates p53 and regulates its activity. J Neurochem 81: 307-313.
• Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6: 31.
• Zhang CE, Tian Q, Wei W, Peng JH, Liu GP, Zhou XW, Wang Q, Wang DW, Wang JZ (2008) Homocysteine induces tau phosphorylation by inactivating protein phosphatase 2A in rat hippocampus. Neurobiol Aging 29: 1654-1665.
• Zhu YS, Saito T, Asada A, Maekawa S, Hisanaga S (2005) Activation of latent cyclin-dependent kinase 5 (Cdk5)- p35 complexes by membrane dissociation. J Neurochem 94: 1535-1545.

Uwagi

Rekord w opracowaniu